Why GDR Matters - In post-acute and long-term care, psychotropic medications such as antipsychotics, antidepressants, and benzodiazepines are common. These medications carry risks including falls, sedation, delirium, and functional decline. CMS requires us to ask regularly: Does this resident still need this medication? This is why there are several opportunities - admission, follow ups, 30-60 day visits and order reviews to re-evaluate medication appropriateness.

Many residents do just as well, or better, after a careful taper. When paired with non-drug approaches, GDR improves safety, quality of life, and survey readiness.

Regulatory Snapshot (Spring 2025 Updates)
Surveyors are paying closer attention than ever. They are looking for:

• F605: All psychotropics must have a clear, ongoing clinical indication.
• PRN limits: Psychotropic PRNs expire after 14 days unless renewed; antipsychotic PRNs require an in-person reassessment.
• Informed consent: Residents or decision-makers must be told risks, benefits, and alternatives before starting or changing medications.
• GDR expectations: In the first year in long-term care, at least two GDR attempts must be made (at least one month apart). After the first year, attempts must occur at least annually (unless clinically contraindicated with documentation).
• Surveyor focus: Surveyors will check that diagnoses, behaviors, and medications align, and that non-drug approaches were tried and documented.

What the Evidence Tells Us

• Antipsychotics: Research shows many residents can stop without worsening behaviors, especially if symptoms were mild. Example: A resident with mild sundowning was tapered off haloperidol after staff set up a calming evening routine. She slept better and was more alert in the mornings.
• Benzodiazepines and Z-drugs: These medications confer high risk for falls and delirium. Example: A man on nightly Ativan had repeated falls. After a slow taper and adding a bedtime ritual with herbal tea, music, and a weighted blanket, his sleep improved and falls stopped.
• Antidepressants: Tapering after 6 to 12 months of remission is often safe with close monitoring, especially for individuals who have not had multiple lifetime episodes of major depressive disorder. Example: A woman stable on sertraline for a year tapered slowly while continuing weekly group therapy. Her mood remained steady, and she avoided long-term side effects.

A Practical Roadmap for GDR

1. Check the reason: What symptom is the medication treating? Is it still present?
2. Involve the team: Nursing, therapy, social services, and families should all know the plan.
3. Taper gradually:
1. Antipsychotics: reduce by 25 to 50 percent every 1 to 2 weeks
2. Benzodiazepines: reduce by 10 to 25 percent every 1 to 2 weeks
3. Antidepressants: reduce by 10 to 25 percent every 2 to 4 weeks
4. Support with non-drug strategies: Routines, redirection, sleep hygiene, pain control, and comfort measures.
5. Document everything: Indication, taper plan, resident response, and reason if continuation is necessary.
6. Documenting appropriateness of psychotropics in hospice patients is also important and tapers can be attempted when appropriate, but comfort is always the first priority in hospice. GDRs should not compromise quality of life.

Key Takeaways for Staff

• GDR is required by CMS and supported by clinical evidence.
• Most residents tolerate tapering and often improve.
• Non-drug approaches are essential, not optional.
• Surveyors will expect to see GDR attempts twice in the first year, then annually.
• If tapering is unsafe, document the reason clearly.
• GDRs are federally required, but should not compromise hospice patient quality of life.

Bottom Line
Gradual dose reductions are not just about compliance. They are about safety, dignity, and quality of life. With careful planning, teamwork, and good documentation, residents can thrive while meeting the latest regulatory expectations.